Pain Therapeutics Revamps Oxytrex Program, Changes Phase III Protocol For Pain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pain Therapeutics' new trial design for Oxytrex features ultra-low doses and a four-times-a-day dosing regimen, CEO Remi Barbier said May 4
You may also be interested in...
PTI’s Oxytrex “Worth One More Shot” After Phase III Study Spoiled By Vioxx
Inappropriate enrollment of former Vioxx patients in Pain Therapeutics’ Phase III trial of Oxytrex for severe osteoarthritic pain undermined the study’s statistical power and necessitates a new trial, according to PTI.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product